Christopher R. Cline, Chief Financial Officer at Travere Therapeutics, Inc. (TVTX), sold 1,588 shares at $21.75 ($35K) on 2023-02-01, disclosed to the SEC on 2023-02-02.
Open-market sale of $35k TVTX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| TVTX | SELL | 2026-05-06 | $115K | — | Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |